Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale.

Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

View Bio-Techne Corporation TECH stock quote prices, financial information, real-time forecasts, and company news from CNN.

The deal, Merck's largest since its Sigma-Aldrich buyout, expands its presence in proteins, spatial biology, and cell and gene therapy ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...

Bio-Techne Corp, has agreed to an acquisition offer by Germany’s Merck KGaA for about $11.3 billion, the largest M&A deal involving a Minnesota company so far this year.

Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered ...

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest deal in over a decade.

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

Shares of U.S. life sciences company Bio-Techne jumped more than +22% in premarket trading on Thursday after Merck KGaA agreed to acquire the company for $73 per share in cash, va ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...